Contact
searchSearch
HMP Global
Login

Interactive Features

Quiz
Improving Detection of Clinically Significant Prostate Cancer
01/15/2024
True or False: Adding the PRIMARY score for patients with Prostate Imaging Reporting and Data System (PI-RADS) 4/5 showed a net benefit in detecting clinically significant prostate cancer.
True or False: Adding the PRIMARY score for patients with Prostate Imaging Reporting and Data System (PI-RADS) 4/5 showed a net benefit in detecting clinically significant prostate cancer.
True or False: Adding the...
01/15/2024
Oncology
Quiz
Adjuvant Radiotherapy Following Radical Prostatectomy
11/13/2023
Allison Casey
Test your knowledge on the results from RADICALS RT trial evaluating adjuvant radiotherapy after radical prostatectomy.
Test your knowledge on the results from RADICALS RT trial evaluating adjuvant radiotherapy after radical prostatectomy.
Test your knowledge on the...
11/13/2023
Oncology
Quiz
Biweekly vs Triweekly Cabazitaxel for Patients With Metastatic Castration-Resistant Prostate Cancer
11/10/2023
Test your knowledge with this quiz on the biweekly cabazitaxel regimen used in the phase 3 CASBASTY trial, for patients with metastatic castration-resistant prostate cancer.
Test your knowledge with this quiz on the biweekly cabazitaxel regimen used in the phase 3 CASBASTY trial, for patients with metastatic castration-resistant prostate cancer.
Test your knowledge with this...
11/10/2023
Oncology
Quiz
Adaptive 177Lu-PSMA-617 Dosing in the ENZA-p Trial
11/10/2023
Test your knowledge with this quiz on the adaptive dosing utilized in the ENZA-p trial, evaluating the addition of 177Lu-PSMA-617 to enzalutamide for patients with metastatic castration-resistant prostate cancer.
Test your knowledge with this quiz on the adaptive dosing utilized in the ENZA-p trial, evaluating the addition of 177Lu-PSMA-617 to enzalutamide for patients with metastatic castration-resistant prostate cancer.
Test your knowledge with this...
11/10/2023
Oncology
Quiz
Adaptive 177Lu-PSMA-617 Dosing in the ENZA-p Trial
11/10/2023
Test your knowledge with this quiz on the adaptive dosing utilized in the ENZA-p trial, evaluating the addition of 177Lu-PSMA-617 to enzalutamide for patients with metastatic castration-resistant prostate cancer.
Test your knowledge with this quiz on the adaptive dosing utilized in the ENZA-p trial, evaluating the addition of 177Lu-PSMA-617 to enzalutamide for patients with metastatic castration-resistant prostate cancer.
Test your knowledge with this...
11/10/2023
Oncology
Quiz
Quiz: Olaparib Added to Abiraterone for Metastatic Castration-Resistant Prostate Cancer
11/30/2022
True or False: In the phase 3 PROpel study, the addition of olaparib to abiraterone improved the radiographic progression-free survival of patients with metastatic castration-resistant prostate cancer, compared to abiraterone alone.
True or False: In the phase 3 PROpel study, the addition of olaparib to abiraterone improved the radiographic progression-free survival of patients with metastatic castration-resistant prostate cancer, compared to abiraterone alone.
True or False: In the phase 3...
11/30/2022
Oncology
Quiz
True or False: A study found that the risk of prostate cancer following a transurethral resection of the prostate with a benign histology was higher than the risk for patients with a negative prostate biopsy.
11/02/2022
True or False: A study found that the risk of prostate cancer following a transurethral resection of the prostate with a benign histology was higher than the risk for patients with a negative prostate biopsy.
True or False: A study found that the risk of prostate cancer following a transurethral resection of the prostate with a benign histology was higher than the risk for patients with a negative prostate biopsy.
True or False: A study found...
11/02/2022
Oncology
Quiz
Quiz: Enzalutamide Plus Testosterone Suppression for Metastatic Hormone-Sensitive Prostate Cancer
09/02/2022
In the ENZAMET trial evaluating the addition of enzalutamide to testosterone suppression for patients with metastatic hormone-sensitive prostate cancer, did the extended follow-up find that the benefit from enzalutamide was sustained at the...
In the ENZAMET trial evaluating the addition of enzalutamide to testosterone suppression for patients with metastatic hormone-sensitive prostate cancer, did the extended follow-up find that the benefit from enzalutamide was sustained at the...
In the ENZAMET trial evaluating...
09/02/2022
Oncology
Quiz
Quiz: Does the Polaris Test Prognosticate Risk of Metastasis in Prostate Cancer?
07/21/2022
Quiz: The commercially-available Polaris test was able to prognosticate the risk of metastasis in which patients with prostate cancer?
Quiz: The commercially-available Polaris test was able to prognosticate the risk of metastasis in which patients with prostate cancer?
Quiz: The commercially-available...
07/21/2022
Oncology
Test Your Knowledge
Quiz: Can the Prolaris Test Estimate Metastasis in Prostate Cancer?
09/02/2021
True or false: For patients with intermediate or high-risk prostate cancer, the Prolaris test can provide an extremely precise and accurate risk estimate of metastasis after radiation therapy.
True or false: For patients with intermediate or high-risk prostate cancer, the Prolaris test can provide an extremely precise and accurate risk estimate of metastasis after radiation therapy.
True or false: For patients with...
09/02/2021
Oncology

Recent News

News
Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Rise
01/29/2026
Stephanie Holland
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world...
01/29/2026
Oncology
News
Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer
01/29/2026
Emily Estrada
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to...
01/29/2026
Oncology
News
Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma
01/28/2026
Stephanie Holland
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2...
01/28/2026
Oncology
News
Advances in Antibody-Based Therapies for the Treatment of Relapsed Small-Cell Lung Cancer
01/27/2026
Gina Tomaine
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are...
01/27/2026
Oncology
News
Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial
01/27/2026
Emily Estrada
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab...
01/27/2026
Oncology
News
TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC
01/27/2026
Emily Estrada
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination...
01/27/2026
Oncology
News
ISL1 Emerges as a Potential Predictive Biomarker for Efficacy of Lurbinectedin in Relapsed SCLC
01/27/2026
Gina Tomaine
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified...
01/27/2026
Oncology
News
CSF-1-Targeted Therapies Continue to Redefine Systemic Treatment for TGCT
01/26/2026
Gina Tomaine
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition...
01/26/2026
Oncology
News
Sacituzumab Govitecan Plus Pembrolizumab Significantly Prolongs PFS in PD-L1-Positive Triple-Negative Breast Cancer
01/22/2026
Stephanie Holland
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3...
01/22/2026
Oncology
News
Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer
01/21/2026
Stephanie Holland
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter,...
01/21/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use